spacer
home > ebr > winter 2018 > training day
PUBLICATIONS
European Biopharmaceutical Review

Training Day

As opposed to traditional pharmaceutical products, biopharmaceuticals are complex high-molecular-weight items of biological origin derived from living organisms, cells, animals or plants. Market predictions strongly suggest that sales of biopharmaceutical products will continue to increase year-on-year, with the market being driven primarily by further increases in sales of recombinant monoclonal antibodies (mAbs) that have proven to be successful therapies for a large number of disease states.

However, the focus on advanced therapy medicinal products is increasing, with some manufacturers looking to diversify into gene therapies, cell therapies and tissue engineering as strategies for pipeline development. By 2020, biopharma sales are estimated to contribute at least 50% of total biopharma and pharma revenues, with the former contributing 80% of product candidates in pipelines (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr John Milne is currently Director of training at the National Institute for Bioprocessing Research and Training. He has been employed in the biopharma industry for 20 years and has performed in a series of roles, including process development, optimisation, scale-up and GMP manufacture of therapeutic proteins and mAbs in regulated facilities. John received his PhD in molecular enzymology from the Department of Biochemistry at University College Dublin.
spacer
Dr John Milne
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Porton Biopharma opens new facility to make more of its childhood cancer cure

In a ribbon cutting ceremony, John Glen MP for Salisbury and South Wiltshire today (27th April 2018) officially opened Porton Biopharma Limited’s (PBL) new fermentation facility which will be used to manufacture the company’s life-saving leukaemia drug Erwinase®.   
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 
Industry Events

HPLC 2018

29 July - 2 August 2018, Washington Marriott Wardman Park, Washington, DC, USA

Are you interested in mass spectrometry, chromatography, or electrophoresis? Are you solving complex analytical problems? Are you looking for a conference with strong scientific content, a robust program, presentations by world renowned experts, lectures by young scientists, courses offering great training opportunities, tutorials, panel discussions, vendor technical workshops, best poster competition, and a major exposition showcasing new product launches and innovative products? Mark your calendar to attend HPLC 2018 Washington, DC, the largest, most recognized international conference in the world devoted to advances in separation technologies!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement